[go: up one dir, main page]

WO2019078463A1 - Composition pour traiter les lésions des cellules de la peau provoquées par la poussière fine, comprenant un extrait de thé vert - Google Patents

Composition pour traiter les lésions des cellules de la peau provoquées par la poussière fine, comprenant un extrait de thé vert Download PDF

Info

Publication number
WO2019078463A1
WO2019078463A1 PCT/KR2018/009261 KR2018009261W WO2019078463A1 WO 2019078463 A1 WO2019078463 A1 WO 2019078463A1 KR 2018009261 W KR2018009261 W KR 2018009261W WO 2019078463 A1 WO2019078463 A1 WO 2019078463A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
green tea
tea extract
fine dust
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/009261
Other languages
English (en)
Korean (ko)
Inventor
신승현
안지연
나용주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of WO2019078463A1 publication Critical patent/WO2019078463A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • compositions for treating skin cell damage caused by fine dusts More particularly, the present invention discloses a composition comprising a tea tree extract, wherein the skin cell damage is cared by significantly changing a biomarker, such as a skin cell gene whose degree of expression is changed by fine dust, as compared with a normal skin cell.
  • a biomarker such as a skin cell gene whose degree of expression is changed by fine dust
  • Fine dusts are smaller in size than normal dusts, so they penetrate the human body more and contain harmful substances such as heavy metals, nitrates, ammoniums, and sulfates, and are harmful to human body.
  • harmful substances such as heavy metals, nitrates, ammoniums, and sulfates
  • the cells responsible for the immune function of the human body act to remove dust. These side effects are accompanied by inflammation.
  • the World Health Organization categorizes fine dusts as a group of carcinogens directly related to cancer.
  • Non-patent document 1 discloses that the expression amount of clodin 1 (CLDN 1), which is a major constituent of tight junction, which is a granule layer barrier, is reduced due to fine dust stimulation of PM 2.5.
  • Non-Patent Document 1 Kim, HJ, et al., "Transcriptome analysis of airborne PM 2.5 -induced detrimental effects on human keratinocytes", Toxicology Letters 273, 26-35,
  • the present inventors have found that the effect of fine dusts on the skin is detrimental to the skin, and the skin cell gene expression is affected by such an effect, thereby manifesting symptoms such as skin cell damage, and the green tea extract has an effect of restoring gene expression Respectively.
  • the present invention provides a composition comprising an extract of green tea as an active ingredient, wherein keratin 1 (KRT 1), claudin 1 CLDN1), claudin 4 (CLDN4), and occludin (OCLN) to a normal level.
  • KRT 1 keratin 1
  • CLDN1 claudin 1
  • CLDN4 claudin 4
  • OCLN occludin
  • the amount of gene expression changed by the fine dust can be returned to a normal level and skin cell damage can be cared.
  • Fig. 1 shows the expression of mRNA of KRT 1 gene in skin cells stimulated by ERM-CZ120 fine powder and showed a return to normal level by green tea extract treatment.
  • FIG. 2 shows an increase in mRNA expression of CLDN 1 gene in skin cells stimulated by ERM-CZ120 fine dust, and a return to a normal level by green tea extract treatment.
  • FIG. 3 shows that mRNA expression of CLDN4 gene was increased in skin cells stimulated by ERM-CZ120 fine powder and returned to normal level by green tea extract treatment.
  • Fig. 4 shows the increase in mRNA expression of OCLN gene in ERM-CZ120 micropore-stimulated skin cells and normalization by green tea extract treatment.
  • the composition for care of skin damage due to fine dust may include green tea extract as an active ingredient.
  • Camellia sinensis is a perennial evergreen plant belonging to theaceae. It is distributed in tropical, subtropical and temperate regions.
  • the main ingredients of tea tree are catechins, caffeine, amino acids, vitamins and minerals. Have been reported to exhibit physiological activity and pharmacological effects. Recently, catechins have been reported to have various functions such as antifouling effect, antioxidant effect, antimicrobial effect and anticancer effect.
  • the green tea extract is green tea leaf extract, the green tea leaves are not fermented, and the inner enzyme is inactive.
  • the green tea may be extracted with a specific extraction solvent to form a green tea extract.
  • the green tea extract may be prepared by extracting green tea with water or an organic solvent.
  • the green tea is prepared by dissolving at least one compound selected from the group consisting of water, C 1 -C 6 anhydrous or lower alcohol, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform, And extracting it with an extraction solvent.
  • the green tea extract may be extracted at room temperature.
  • the green tea extract may be one obtained by extracting with the extraction solvent, followed by addition of one or more of evaporation, filtration, concentration, separation or drying.
  • the green tea extract may be subjected to one or more filtration processes.
  • the separation process may include a centrifugation process.
  • the extraction can be carried out in the presence of water, a C 1 -C 6 anhydrous or a lower alcohol, a polar solvent comprising acetone and butylene glycol, and a polar solvent including ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane
  • a low polarity solvent may be used as a solvent.
  • the solvent may be 10-90% ethanol aqueous solution, and may be 10-50%, 15-45%, or 20-40% ethanol aqueous solution.
  • the solvent is 20 to 40% aqueous ethanol solution, the effective ingredient can be effectively extracted from the green tea.
  • the solvent is about 30% aqueous ethanol.
  • the extract may be concentrated under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser after extraction.
  • the green tea extract according to the present invention can be extracted by a conventional method in the art, and is not limited by the above-described method.
  • the composition may comprise from 0.000001 to 30% by weight of green tea extract, based on the total weight of the composition.
  • the content thereof is 0.000001 to 30% by weight, the effect of care for skin damage due to fine dust caused by green tea extract is excellent.
  • 0.0000001 wt% or more 0.0000005 wt% or more, 0.0000007 wt% or more, 0.0000009 wt% or more, 0.0000009 wt% or more, 0.000001 wt% or more, 0.000002 wt% or more, 0.000004 wt% or more, 0.000006 wt% or more, 0.000008 wt.
  • % 0.0000007 wt% or less, 0.0000005 wt% or less, 0.0000003 wt% or less, 0.0000002 wt% or less, 0.0000001 wt% or less, or 0.00000009 wt% or less.
  • the active ingredient of the composition according to the present invention may be one which acts on the tight junction of the skin barrier.
  • the tight junction is a kind of cell junction, consisting of claudin, tricellulin, junctional adhesion molecule (JAM) and zona occluden (ZO).
  • the tight junction can be divided into a part contained in the cell membrane and an intracellular part.
  • Occludin and claudin are closely related constitutive proteins contained in cell membranes.
  • Occludin is the first transmembrane protein found in adherent synapses and has four transmembrane domains.
  • Occludin is known to regulate the function of tight junctions as well as constituents of tight junctions.
  • Claudin a close-coupled conformational protein with Occludin, also has four transmembrane domains.
  • the tight junction is a cell-to-cell linkage that fills the gap between neighboring cells, controls the movement of small molecules, controls the permeation of cells between cells, and maintains the polarity of the cells. Recently, it has been reported that tight junctions play an important role in skin barrier function. Tight junctions are a type of intercellular binding. It is a cell-to-cell junction that mainly occurs in epithelial cells and endothelial cells, forming a complex network with a string-like structure. The tight junction has two functions largely from this structure. The first is a barrier function that prevents material from leaking into the cells that make up epithelial cells or endothelial cells. It is mainly treated in blood vessels and digestive tracts.
  • the second is a fence function, which is a function to divide the cell membrane around the membrane fence in the cell membrane lipid. Accordingly, the active ingredient of the composition of the present invention acts on the tight junction of the skin barrier, thereby enhancing the barrier function and the fence function of the skin cells, thereby protecting the skin damaged by the fine dust stimulation.
  • Another aspect of the present invention includes skin care care applications for fine dusts of the composition.
  • a method for skin damage care by fine dust of a subject comprising administering an effective amount of a green tea extract to a subject in need thereof.
  • Another aspect of the present invention provides the use of green tea extract in the preparation of a composition for skin damage care by fine dust.
  • fine dust refers to a particulate matter that is a very small material that is invisible to the naked eye and that floats or drifts in the air for a long time.
  • the particle size of fine dust in the present invention may be not more than 10 ⁇ m (PM 10), specifically not more than 2.5 ⁇ m (PM 2.5).
  • Particulate matter having a particle diameter of not more than 2.5 ⁇ m (PM 2.5) is referred to as "ultrafine dust”.
  • fine dust is also intended to include “ultrafine dust”.
  • the fine dust in the present invention may include one or more of arsenic, cardmium, lead, and nickel.
  • the heavy metal components such as arsenic, cardmium, lead, and nickel are included in the fine dust to attack skin cells and cause skin allergy, pigmentation, inflammation, .
  • the fine dust includes arsenic, cardmium, lead, and nickel.
  • care means to effectively protect skin cells from stimulation and to inhibit, prevent, and restore (restore) the expression level of a specific gene by the stimulation.
  • repair also includes improving the expression level beyond the reference, in addition to changing the expression level closer to the reference level based on the gene expression level in the absence of the stimulus.
  • the present invention provides a composition for inhibiting damage of skin cells caused by fine dusts by controlling the expression level of a specific gene in skin cells damaged by fine dust to a normal level.
  • genes in the skin cells to which the expression amount by the fine dust is affected include keratin 1 (KRT 1), cladin 1 (CLDN 1), cladin 4 (CLDN 4), and occludin And at least one selected from the group. Since keratin 1 (KRT 1), claudin 1 (CLDN 1), claudin 4 (CLDN 4), and occludin (OCLN) are genes whose expression amount is reduced by fine dusts, To inhibit skin cell damage.
  • Analysis of the expression level of the gene or protein can be performed using a microarray, PCR, NGS (Nest Generation Sequencing), Western blot, northern blot, ELISA, radioimmunoassay, radioimmunoassay, tissue immuno staining, Can be analyzed using a variety of analytical methods known in the art.
  • Damage to the skin cells is caused by fine dust, which leads to inflammation and further damage to the skin cells.
  • the skin condition can be improved by taking care of the vicious circle of the skin cell damage by the green tea extract.
  • the composition may be a cosmetic composition, a pharmaceutical composition, or a health functional food composition.
  • cosmetic composition examples include cosmetics such as various creams, lotion creams, lotions, skins, and the like, and cleansing, cleansing agents, soaps, and essences.
  • the cosmetic composition to which the composition containing the green tea extract of the present invention is added may take the form of a solution, an emulsion, a viscous mixture or the like.
  • the cosmetic of the present invention is not particularly limited in its formulation, and examples thereof include an emulsion, cream, lotion, essence, pack, gel, powder, makeup base, foundation, lotion, ointment, patch, Formulations such as foam, cleansing cream, cleansing water, body lotion, body cream, body oil, body essence, shampoo, rinse, body cleanser, soap, hair dye, spray and the like.
  • the components other than the green tea extract may be mixed and selected without difficulty by those skilled in the art depending on the formulation or use of the other cosmetic ingredients.
  • the cosmetic of the present invention may comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
  • the cosmetic composition of the present invention may contain, in addition to the above essential ingredients, other ingredients usually added to cosmetics, if necessary.
  • Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
  • organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorbent, a preservative, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation accelerator, a cold agent, an antiperspirant agent, and purified water.
  • the components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.
  • the pharmaceutical compositions comprising the green tea extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.
  • the pharmaceutical composition containing the green tea extract may be formulated into tablets, capsules, powders or syrups, or external preparations such as ointments, gels, creams, patches or sprays, And may be formulated and used in any form suitable for a clinical formulation.
  • the actual dosage of the active ingredient administered by the pharmaceutical composition should be determined in light of various relevant factors such as the severity of the symptoms, the route of administration selected, the age, sex, weight and health status of the subject.
  • the dosage of the active ingredient may be from 0.0001 mg / kg / day to 3000 mg / kg / day, for example from 10 mg / kg / day to 500 mg / kg / day.
  • the health food is produced by using a raw material or a component (functional raw material) having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions.
  • a raw material or a component having a function useful for a nutrient or a human body which is likely to be deficient in a daily meal, Or to maintain or improve health through the activation of physiological functions.
  • the present invention is not limited thereto.
  • the health food may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and circles, but is not limited thereto and may be manufactured and processed in any form according to the law.
  • the health beverage composition has no particular limitation on the other ingredients other than the above-mentioned compounds as essential ingredients in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients such as ordinary beverages.
  • natural carbohydrates are conventional sugars such as monosaccharide polysaccharides, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • Natural flavors tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be used as flavorings other than those described above.
  • the actual dosage of the active ingredient administered by the health functional food composition should be determined in light of various relevant factors such as the severity of the symptoms, the selected route of administration, the age, sex, weight and health status of the subject .
  • the dosage of the active ingredient may be from 0.0001 mg / kg / day to 1000 mg / kg / day, for example from 0.02 mg / kg / day to 6 mg / kg / day.
  • Green tea extracts were prepared using green tea from Amorepacific Group Changwon. The collected green tea leaves were washed with purified water, filtered and dried, and then mixed in a weight ratio of 1: 8 with 30% ethanol (EtOH). The mixture was stirred at 25 ° C for 72 hours and extracted into 250 mesh size.
  • the obtained extract was subjected to three filtration steps, each of which had a size of 3.0 ⁇ m or less, a size of 1.0 ⁇ m or less, and a size of 0.3 ⁇ m or less.
  • the filtered extract was settled at 4 DEG C for 72 hours, and then filtered again to a size of 0.2 mu m or less to prepare a green tea extract.
  • Keratinocyte cell line Human normal epidermal keratinocytes was Lonza ⁇ (Lonza, Inc. Walkersville, Maryland material) was purchased and subcultured in a culture under a CO 2 incubator (CO 2 incubator), 37 °C from, 5% CO 2 conditions Respectively.
  • Bovine pituitary extract (BPE), human epidermal growth factor (hEGF), insulin, hydrocortisone, gentamicin sulfate, and the like were added to 500 ml of KBM-2 (KBMTM-2, CC- (Gentamycin Suflate), Epinephrine, and Transferrin were used.
  • the fine dusts were ERM-CZ120 fine dusts commercially available from Sigma-Aldrich, and PM 10 levels of fine dust and arsenic, cardmium, lead, and nickel ).
  • a 6-well plate was used and 1 ' Cells cultured under the conditions of 3 ⁇ 10 5 cells / well (cells / well) were cultured in the untreated group (control 1), 50 ppm of fine dusts (Control group 2), and a group treated with 50 ppm of fine dust and green tea extract (Example 1), respectively, and then cultured for 3 hours and 6 hours.
  • Control 1 The cells were washed with 2 ml of phosphate buffered saline (PBS) in Control 1, Control 2 and Example 1 obtained in the treatment of fine dust and green tea extract on keratinocyte cell line, Trizol reagent, Invitrogen, Carlsbad, CA, USA).
  • PBS phosphate buffered saline
  • RNA kit QIAGEN RNeasykt, QIAGEN, Valencia, Calif.
  • Agilent Technologies, Inc. Agilent 2100 BioAnalyzer, Agilent Technologies, Santa Clara, ) was used to confirm the quality of the RNA.
  • CDNA was synthesized from RNA using Invitrogen's Reverse Kit (Superscript Reverse Transcriptase (RT) kit, Invitrogen, Carlsbad, Calif.).
  • Q-RT-PCR real-time reverse transcription polymerase chain reaction
  • the control group 2 treated with fine dust at a concentration of 50 ppm contained Keratin 1, Claudin 1, Claudin 1, 4 (Claudin 4), and Occludin (mRNA) of the present invention.
  • the amount of mRNA expression of keratin 1 was 0.19 for 3 hours and 0.13 for 6 hours, indicating that mRNA expression levels were significantly decreased in the keratin 1, 0.44 and 0.24 in the keratin 1 and 0.52 in the keratin 4, respectively , And acrodine decreased to 0.48 and 0.39, respectively. That is, the amount of expression of keratinocyte differentiation markers (ie, keratin 1) and tight junction components (ie, claudin 1, claudin 4, and occludin) in the granule barriers were all reduced by fine dust.
  • Example 1 shows that the green tea extract of the present invention can cure mRNA expression levels of markers reduced by fine dust.
  • FIG. 1 shows that the amount of mRNA expression of keratin 1 is restored by 0.79 for 3 hours and 0.99 for 6 hours
  • FIG. 4 shows the expression level of mucin Was 0.88 for 3 hours and 0.98 for 6 hours, indicating that the amount of mRNA decreased by fine dust was restored.
  • Claudin 1 and Claudin 4 exhibited enhanced mRNA expression levels (1.12 and 1.23, respectively, when treated for 3 hours, and 1.23 and 1.45, respectively, when treated for 6 hours), compared to control group 1 (see FIGS. 2 and 3).
  • the cosmetic composition, the pharmaceutical composition and the health functional food composition can be applied to various formulations, and the present invention is not limited thereto .
  • 100 mg of the green tea extract according to the present invention, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate were mixed and then tableted according to the conventional preparation method.
  • Green tea extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2
  • 100 mg of the green tea extract according to the present invention, 400 mg of lactose, 400 mg of corn starch and 2 mg of magnesium stearate were mixed and filled in gelatin capsules according to the conventional preparation method of capsules to prepare capsules.
  • Green tea extract 100 Lactose 400 Corn starch 400 Magnesium stearate 2
  • green tea extract according to the present invention 250 mg of anhydrous crystalline glucose and 550 mg of starch were mixed and granulated into granules using a fluidized bed granulator, and filled in a capsule.
  • Green tea extract 5.00 maintain Suitable amount Sodium hydroxide Suitable amount Sodium chloride Suitable amount Spices Suitable amount Purified water Balance
  • Green tea extract 3.00 Polyethylene glycol monostearate 2.00 Self emulsifying monostearic acid glycerin 5.00 Cetyl alcohol 4.00 Squalene 6.00 Tri-2-ethylhexanoic acid glyceryl 6.00 Sphingoglycolipids 1.00 1,3-butylene glycol 7.00 Purified water Balance
  • Vitamin A acetate 70 ⁇ g Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 ⁇ g Vitamin C 10 mg Biotin 10 ⁇ g Nicotinic acid amide 1.7 mg Folic acid 50 ⁇ g Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg
  • Green tea extract 50 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1g Purified water Balance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition comprenant comme principe actif un extrait de thé vert destinée au traitement des lésions cutanées provoquées par la poussière fine, qui permet de ramener à un niveau normal l'expression d'au moins un élément appartenant au groupe constitué par KRT 1, CLDN 1, CLDN 4 et OCLN, qui tous sont des gènes dont le niveau d'expression dans les cellules de la peau est affecté par la poussière fine. L'utilisation de la composition de l'invention permet de ramener à un niveau normal l'expression des gènes qui était modifiée par la poussière fine et ainsi traiter les lésions des cellules de la peau.
PCT/KR2018/009261 2017-10-20 2018-08-13 Composition pour traiter les lésions des cellules de la peau provoquées par la poussière fine, comprenant un extrait de thé vert Ceased WO2019078463A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136562A KR102200016B1 (ko) 2017-10-20 2017-10-20 녹차 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
KR10-2017-0136562 2017-10-20

Publications (1)

Publication Number Publication Date
WO2019078463A1 true WO2019078463A1 (fr) 2019-04-25

Family

ID=66174031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009261 Ceased WO2019078463A1 (fr) 2017-10-20 2018-08-13 Composition pour traiter les lésions des cellules de la peau provoquées par la poussière fine, comprenant un extrait de thé vert

Country Status (2)

Country Link
KR (1) KR102200016B1 (fr)
WO (1) WO2019078463A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210152938A (ko) 2020-06-09 2021-12-16 (주)아모레퍼시픽 미세먼지 대기환경 내 지속적 노출에 의한 호흡기 건강 개선을 위한 조성물
TWI877365B (zh) 2020-06-09 2025-03-21 南韓商愛茉莉太平洋股份有限公司 以綠茶提取物、綠茶多糖及綠茶黃酮醇作為製備用於改善暴露於微塵下呼吸道健康的用途及用於降低血液中重金屬濃度的組合物中的用途
KR102887369B1 (ko) * 2020-07-21 2025-11-14 (주)아모레퍼시픽 피부 각질의 분화 이상 정상화용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050054532A (ko) * 2003-12-05 2005-06-10 염재한 녹차 세정수
KR20090006385A (ko) * 2007-07-11 2009-01-15 고려대학교 산학협력단 여드름, 아토피 피부 질환 예방 및 치료용 녹차 수용성추출물의 제조방법
KR20090056479A (ko) * 2007-11-30 2009-06-03 (주)아모레퍼시픽 녹차를 이용한 염모제 조성물
KR101653755B1 (ko) * 2016-01-06 2016-09-02 주식회사 씨앤피코스메틱스 미세먼지 차단용 화장료 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050054532A (ko) * 2003-12-05 2005-06-10 염재한 녹차 세정수
KR20090006385A (ko) * 2007-07-11 2009-01-15 고려대학교 산학협력단 여드름, 아토피 피부 질환 예방 및 치료용 녹차 수용성추출물의 제조방법
KR20090056479A (ko) * 2007-11-30 2009-06-03 (주)아모레퍼시픽 녹차를 이용한 염모제 조성물
KR101653755B1 (ko) * 2016-01-06 2016-09-02 주식회사 씨앤피코스메틱스 미세먼지 차단용 화장료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
20 March 2015 (2015-03-20), pages 1 - 3, Retrieved from the Internet <URL:http://www.stnews.co.kr/news/articleView.html?idxno=3841> *
vol. 1, 13 April 2016 (2016-04-13), Retrieved from the Internet <URL:http://www.hani.co.kr/arti/specialsection/esc_section/739543.html> *

Also Published As

Publication number Publication date
KR102200016B1 (ko) 2021-01-08
KR20190044303A (ko) 2019-04-30

Similar Documents

Publication Publication Date Title
EP3119382B1 (fr) Applications cosmetiques et pharmaceutiques de la vescalagine et de la castalagine
KR102267796B1 (ko) 천연 추출물 유래 엑소좀을 유효성분으로 포함하는 피부 진정용 조성물
WO2017003086A1 (fr) Composition permettant d&#39;inhiber et de prévenir la myopathie, contenant un extrait de feuilles de haricot en tant que principe actif
TW200533333A (en) Human beta-defensin production accelerator
WO2019078463A1 (fr) Composition pour traiter les lésions des cellules de la peau provoquées par la poussière fine, comprenant un extrait de thé vert
EP3478051A1 (fr) Cultures de lignées cellulaires provenant de plantes appartenant au genre harpagophytum
CN111315357B (zh) 含有源自绿茶的乳酸菌的用于护理由微尘引起的皮肤细胞损伤的组合物
WO2019059527A1 (fr) Composition pour traiter des lésions cutanées provoquées par une poussière fine, comprenant un extrait de fleur de prunus mume
CN104203249B (zh) 用于增强皮肤防御能力的组合物
WO2020111674A1 (fr) Composition contenant des bactéries lactiques dérivées de thé vert pour le soin de la perte des cheveux provoquée par de la poussière fine
KR102164345B1 (ko) 발효차 추출물을 포함하는 피부장벽 강화용 조성물
KR20190061836A (ko) 동백 유래 유산균을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
AU2018341302B2 (en) Antioxidizing, antiaging, or anti-inflammatory composition for strengthening skin barrier and caring for skin cell damage caused by fine dust including fermented tea extract
KR102087189B1 (ko) 무궁화 추출물을 포함하는 항균성 펩티드 저해용 조성물
KR102212626B1 (ko) 박하초 추출물을 포함하는 피부장벽 강화용 조성물
WO2019004590A1 (fr) Composition pour le traitement de lésions des cellules de la peau provoquées par des poussières fines, pour le renfort de la barrière cutanée, et pour la lutte contre le vieillissement ou l&#39;inflammation, contenant un extrait de mentha arvensis
KR102429851B1 (ko) 차나무 뿌리 추출물을 포함하는 항노화 또는 항염 조성물
KR102429850B1 (ko) 차나무 뿌리 추출물을 포함하는 피부장벽 강화용 조성물
CN104244961A (zh) 松萝属地衣类提取物的制造方法
WO2019066252A2 (fr) Composition pour traiter des lésions cellulaires cutanées provoquées par les poussières fines ou pour inhiber un peptide antibactérien, comprenant un extrait d&#39;hibiscus syriacus
JP6667773B1 (ja) 炎症性サイトカイン産生抑制用の組成物
KR20190038115A (ko) 발효차 추출물을 포함하는 항산화, 항노화 또는 항염 조성물
KR20190003145A (ko) 박하초 추출물을 포함하는 항노화 또는 항염 조성물
KR102429852B1 (ko) 차나무 뿌리 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물
KR102212627B1 (ko) 박하초 추출물을 포함하는 미세먼지에 의한 피부 세포 손상 케어용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18867598

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18867598

Country of ref document: EP

Kind code of ref document: A1